ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Home ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

/ Publications

Share the Post

About the Author

Related Posts

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Read More
Anupam Dalal, MD
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

Comments

Comments are closed.